Home › Kidney Cancer (Renal Cell Carcinoma) › California › San Diego
Kidney Cancer (Renal Cell Carcinoma) clinical trials in San Diego, CA
14 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in and around San Diego (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RecruitingPhase 1
- Research Site, San Diego
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- NEO-811 San Diego Site, San Diego
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RecruitingPhase 1
- University of California San Diego Moores Cancer Center, La Jolla · 11 mi away
DESTINY-PANTUMOUR04
RecruitingObservational study
- Research Site, San Diego
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- University of California San Diego, La Jolla · 11 mi away
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RecruitingPhase 2
- University of California San Diego, La Jolla · 11 mi away
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RecruitingPhase 2
- UC San Diego Medical Center - Hillcrest, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi away
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- UC San Diego Medical Center - Bankers Hill, San Diego
- UC San Diego McGrath Outpatient Pavilion - Hillcrest, San Diego
- UC San Diego Medical Center - Hillcrest, San Diego
- and 5 more
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- University of California San Diego Medical Center, Moores Cancer Center, La Jolla · 11 mi away
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- University of California, San Diego, La Jolla · 11 mi away
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RecruitingPhase 3
- UC San Diego Medical Center - Hillcrest, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi away
Retifanlimab and Ruxolitinib In Solid Malignancies
RecruitingPhase 1/2
- University of California, San Diego Moores Cancer Center, La Jolla · 11 mi away
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- UCSD Moores Cancer Center, La Jolla · 11 mi away
A Beta-only IL-2 ImmunoTherapY Study
RecruitingPhase 1/2
- Sharp Memorial Hospital, San Diego
Kidney Cancer (Renal Cell Carcinoma) trials in other cities
- Houston, TX35 studies
- New York City, NY27 studies
- Nashville, TN23 studies
- Dallas, TX23 studies
- St. Louis, MO23 studies
- Los Angeles, CA20 studies
- Boston, MA16 studies
- Baldwin Park, CA16 studies
- Philadelphia, PA15 studies
- Pittsburgh, PA15 studies
- Queens, NY15 studies
- Rochester, MN14 studies
Other studies in San Diego
- Non-Small Cell Lung Cancer48 studies
- Breast Cancer41 studies
- Cancer (all types)32 studies
- Prostate Cancer31 studies
- Metastatic Cancer30 studies
- Colorectal Cancer25 studies
- Ovarian Cancer24 studies
- Pancreatic Cancer24 studies
- Lung Cancer23 studies
- Obesity23 studies
- Heart Failure23 studies
- Depression21 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.